SCHEMBL2546596

SCHEMBL2546596

CN1CCC(CC(=O)Nc2nc3ccc(Sc4cnc5ncccn45)cc3s2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
MET P08581 1/20 0.44
USP30 Q70CQ3 2/20 0.43
CSNK1D P48730 1/20 0.43
SMN1; SMN2 Q16637 6/20 0.43
KMT2A Q03164 6/20 0.43
RAB9A P51151 5/20 0.43
MEN1 O00255 5/20 0.43
NPC1 O15118 4/20 0.43
KDM4E B2RXH2 3/20 0.43
LCK P06239 1/20 0.42
POLB P06746 1/20 0.40
LMNA P02545 4/20 0.39
STAT1 P42224 1/20 0.39
MAPT P10636 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
GAA P10253 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2543258 0.92 RAB9A (0.42) ALDH1A1METUSP30CSNK1DSMN1; SMN2
SCHEMBL2544077 0.91 MET (0.45) ALDH1A1METUSP30CSNK1DSMN1; SMN2
SCHEMBL2545248 0.90 MET (0.40) ALDH1A1METUSP30CSNK1DSMN1; SMN2
SCHEMBL2541762 0.88 MET (0.38) ALDH1A1METUSP30CSNK1DSMN1; SMN2
SCHEMBL1836576 0.87 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2KMT2AMEN1KDM4E
SCHEMBL2537528 0.87 CSNK1D (0.38) ALDH1A1METUSP30CSNK1DSMN1; SMN2
SCHEMBL2541005 0.87 ACHE (0.46) ALDH1A1SMN1; SMN2RAB9ANPC1POLB
SCHEMBL2543190 0.85 RAB9A (0.39) ALDH1A1METUSP30CSNK1DSMN1; SMN2
SCHEMBL2545660 0.85 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2KMT2AMEN1KDM4E
SCHEMBL2540705 0.84 RAB9A (0.42) ALDH1A1SMN1; SMN2KMT2ARAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110263593-A1 NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS SANOFI-AVENTIS (FR) 2011-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263593-A1 NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS TPMT, MET, PAICS ALDH1A1 250/4885MET 2/4885USP30 3876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.